m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT00679
 [1], [2], [3], [4]
m6A modification MicroRNA-92a MicroRNA-92a METTL3 Methylation : m6A sites Indirect Enhancement RNA modification KLF4 KLF4 FTO Demethylation : modification sites
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target microRNA-92a
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type RNA modification (RNAMod)  >> N6,2'-O-dimethyladenosine (m6Am)
Epigenetic Regulator Fat mass and obesity-associated protein (FTO) ERASER View Details
Regulated Target Krueppel-like factor 4 (KLF4) View Details
Crosstalk Relationship m6A  →  m6Am Enhancement
Crosstalk Mechanism m6A modification indirectly impacts RNA modification through downstream signaling pathways
Crosstalk Summary METTL3 interacts with microRNA-92a, decreasing its m6A level and promoting its physical interaction with Krueppel-like factor 4 (KLF4), which was regulated by FTO-mediated m6Am modification.
In-vitro Model
 MHCC97-H Adult hepatocellular carcinoma Homo sapiens CVCL_4972
MKN45 Gastric adenocarcinoma Homo sapiens CVCL_0434
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Krueppel-like factor 4 (KLF4) 1 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name APTO-253 Phase 1 [5]
MOA Inhibitor
External Link
CID: 11960271
TTD: D07TRP
References
Ref 1 AMD1 upregulates hepatocellular carcinoma cells stemness by FTO mediated mRNA demethylation. Clin Transl Med. 2021 Mar;11(3):e352. doi: 10.1002/ctm2.352.
Ref 2 N(6)-methyladenosine-dependent pri-miR-17-92 maturation suppresses PTEN/TMEM127 and promotes sensitivity to everolimus in gastric cancer. Cell Death Dis. 2020 Oct 9;11(10):836. doi: 10.1038/s41419-020-03049-w.
Ref 3 MiR-92a inhibits proliferation and promotes apoptosis of OSCC cells through Wnt/beta-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 2020 May;24(9):4803-4809. doi: 10.26355/eurrev_202005_21169.
Ref 4 Inhibition of MicroRNA-92 alleviates atherogenesis by regulation of macrophage polarization through targeting KLF4. J Cardiol. 2022 Mar;79(3):432-438. doi: 10.1016/j.jjcc.2021.10.015. Epub 2021 Nov 5.
Ref 5 Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors. Invest New Drugs. 2015 Oct;33(5):1086-92. doi: 10.1007/s10637-015-0273-z. Epub 2015 Aug 14.